Advancing the future of obesity

We’re developing next-generation therapeutics that precisely target fat loss while protecting lean muscle mass, advancing a new era of safe, effective, and sustainable obesity care.

Our proprietary drug platform is built on next-generation GLP-1 analogs and metabolic modulators.

Our Pipeline

We’re developing first-in-class small molecules and peptide therapeutics to unlock a healthier metabolism safely and effectively.

Phase 1
Program

INHBE (Activin E)

Indication

Obesity

Est. Ph I Initiation

Q4 2025

Modality

siRNA
Preclinical
Program

Myostatin (GDF8)

Indication

Obesity

Est. Ph I Initiation

H2 2025

Modality

Half-life extended monoclonal antibody

Join the Future of Weight Management

We are currently enrolling participants in early-stage clinical studies. If you’re living with obesity or metabolic syndrome, you may qualify to participate in our groundbreaking research.

Contact

Information

Join our mail list

"*" indicates required fields

Get in touch!

Compose the future with us

"*" indicates required fields

This field is for validation purposes and should be left unchanged.